Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
NCT06088056Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Fudan University. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06088056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088056.